Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...

OZURDEX® was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ...

We read with interest the recently published article by Wai Ch’ng et al entitled ‘Anterior vitreous displacement of the intravitreal dexamethasone implant (Ozurdex)’ 1 and wish to share our similar ...

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has approved Ozurdex for the general patient population being treated for ...

The US Food and Drug Administration has approved Allergan's Ozurdex (dexamethasone intravitreal implant) 0.7 mg for use in adult patients with diabetic macular edema who have had an artificial lens ...

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective ...

June 19 -- THURSDAY, June 18 (HealthDay News) -- An injectable eye implant approved by the U.S. Food and Drug Administration Thursday is the first product sanctioned to treat the eye disorder macular ...

Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss. Cost ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today announced updates on three of the Company’s key R&D pipeline programs, including abicipar pegol ...

To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Ozurdex implant could be a good ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...